Literature DB >> 15834763

Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life.

Christiane Magerkurth1, Rita Schnitzer, Stefan Braune.   

Abstract

Frequency and clinical importance of autonomic failure in idiopathic Parkinson's disease (PD) are discussed controversially. 141 patients with PD and 50 healthy age-matched control subjects were interviewed for symptoms of autonomic failure and their influence on daily life using a questionnaire. In PD patients, the prevalence of orthostatic dizziness, bladder dysfunction, erectile dysfunction and hyperhidrosis was significantly higher compared with controls. About 50% of PD patients rated the impact of the symptoms of autonomic failure on their daily lives as "a lot" or "very much" due to orthostatic dizziness, bladder dysfunction and constipation, which were more statistically significant than in age-matched controls. Prevalence and number of autonomic symptoms were not correlated with duration and severity of PD. In 32% of patients, impaired cardiovascular regulation was found by standardized cardiovascular function tests. If testing showed abnormal findings, orthostatic dizziness, bladder dysfunction, constipation and erectile dysfunction were significantly more frequent than in patients with normal regulation, but the impact on daily life due to these symptoms differed significantly only for bladder dysfunction between groups. It is concluded that autonomic failure is a clinically relevant, pervasive problem in PD and compromise patients' daily life activities in all stages of the disease. This underlines the necessity to adequately search for and treat these non-dopaminergic symptoms during the whole course of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834763     DOI: 10.1007/s10286-005-0253-z

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  25 in total

1.  Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy.

Authors:  S Braune; M Reinhardt; R Schnitzer; A Riedel; C H Lücking
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  Autonomic dysfunction in men with Parkinson's disease.

Authors:  C Singer; W J Weiner; J R Sanchez-Ramos
Journal:  Eur Neurol       Date:  1992       Impact factor: 1.710

3.  Use of the photoplethysmographic technique to analyze the Valsalva maneuver in normal man.

Authors:  E E Benarroch; T L Opfer-Gehrking; P A Low
Journal:  Muscle Nerve       Date:  1991-12       Impact factor: 3.217

4.  Autonomic deficits in Parkinson's syndrome.

Authors:  O Appenzeller; J E Goss
Journal:  Arch Neurol       Date:  1971-01

5.  Autonomic dysfunction in Parkinson's disease.

Authors:  C G Goetz; W Lutge; C M Tanner
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

6.  Urethral sphincter abnormalities in Parkinsonism.

Authors:  N T Galloway
Journal:  Br J Urol       Date:  1983-12

Review 7.  Neuropathology of autonomic nervous system in Parkinson's disease.

Authors:  K Wakabayashi; H Takahashi
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

8.  Prevalence of orthostatic hypotension in Parkinson's disease.

Authors:  J M Senard; S Raï; M Lapeyre-Mestre; C Brefel; O Rascol; A Rascol; J L Montastruc
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-11       Impact factor: 10.154

9.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

10.  Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.

Authors:  C Sachs; B Berglund; L Kaijser
Journal:  Acta Neurol Scand       Date:  1985-01       Impact factor: 3.209

View more
  42 in total

Review 1.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

2.  Autonomic and cognitive dysfunction in Parkinson's disease.

Authors:  Juan Idiaquez; Eduardo E Benarroch; Hugo Rosales; Pablo Milla; Lily Ríos
Journal:  Clin Auton Res       Date:  2007-03-27       Impact factor: 4.435

Review 3.  [Nonmotor symptoms in Parkinson's disease].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

Review 4.  Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease.

Authors:  Katherine E McDonell; Cyndya A Shibao; Daniel O Claassen
Journal:  Curr Neurol Neurosci Rep       Date:  2015-12       Impact factor: 5.081

Review 5.  Gene therapy: a viable therapeutic strategy for Parkinson's disease?

Authors:  Alexander L Berry; Thomas Foltynie
Journal:  J Neurol       Date:  2010-10-21       Impact factor: 4.849

Review 6.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

7.  Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Authors:  Manja Reimann; Claudia Schmidt; Birgit Herting; Silke Prieur; Susann Junghanns; Katherine Schweitzer; Christoph Globas; Ludger Schoels; Heinz Reichmann; Daniela Berg; Tjalf Ziemssen
Journal:  J Neural Transm (Vienna)       Date:  2009-09-17       Impact factor: 3.575

Review 8.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 9.  Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease.

Authors:  Cyndya A Shibao; Horacio Kaufmann
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.